(Q53131141)

English

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors.

scientific article published on 2 April 2016

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27039386

A phase I, dose escalation, pharmacodynamic, pharmacokinetic, and food-effect study of α2 integrin inhibitor E7820 in patients with advanced solid tumors. (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27039386

pharmacodynamics

1 reference

based on heuristic

inferred from title

pharmacokinetics

1 reference

based on heuristic

inferred from title

Alastair Peter Greystoke

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

author name string

B Milojkovic Kerklaan

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

S Slater

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Flynn

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

P O Witteveen

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Megui-Roelvink

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

F de Vos

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

L Reyderman

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

L Ottesen

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M Ranson

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

M P J Lolkema

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

R Plummer

13

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

R Kristeleit

14

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

T R J Evans

15

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

J H M Schellens

16

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

publication date

2 April 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 May 2018

http://europepmc.org/abstract/MED/27039386

Investigational New Drugs

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

34

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

329-337

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

https://scigraph.springernature.com/pub.10.1007/s10637-016-0344-9

0 references

Vascular integrins: therapeutic and imaging targets of tumor angiogenesis

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Integrins: players in cancer progression and targets in cancer therapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Integrins: roles in cancer development and as treatment targets

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Evaluation of α2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Effects of low-fat and high-fat meals on steady-state pharmacokinetics of lapatinib in patients with advanced solid tumours.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

A multicenter phase 1 study of EMD 525797 (DI17E6), a novel humanized monoclonal antibody targeting αv integrins, in progressive castration-resistant prostate cancer with bone metastases after chemotherapy

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

A randomised, phase II study of intetumumab, an anti-αv-integrin mAb, alone and with dacarbazine in stage IV melanoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Phase Ib safety and pharmacokinetic study of volociximab, an anti-α5β1 integrin antibody, in combination with carboplatin and paclitaxel in advanced non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma.

1 reference

https://api.crossref.org/works/10.1007%2FS10637-016-0344-9

21 January 2018

Phase 1 trial of the antiangiogenic peptide ATN-161 (Ac-PHSCN-NH(2)), a beta integrin antagonist, in patients with solid tumours

1 reference

https://pubmed.ncbi.nlm.nih.gov/27039386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium

1 reference

https://pubmed.ncbi.nlm.nih.gov/27039386

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10637-016-0344-9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:27039386%20AND%20SRC:MED&resulttype=core&format=json

2 June 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q53131141&oldid=2144574915"